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Abstract: Amyloid-b peptide (Ab) oligomers may represent the proximal neurotoxin in Alzhei-
mer’s disease. Single-molecule microscopy (SMM) techniques have recently emerged as a
method for overcoming the innate difficulties of working with amyloid-b, including the peptide’s
low endogenous concentrations, the dynamic nature of its oligomeric states, and its heteroge-
neous and complex membrane interactions. SMM techniques have revealed that small oligom-
ers of the peptide bind to model membranes and cells at low nanomolar-to-picomolar
concentrations and diffuse at rates dependent on the membrane characteristics. These meth-
ods have also shown that oligomers grow or dissociate based on the presence of specific
inhibitors or promoters and on the ratio of Ab40 to Ab42. Here, we discuss several types of
single-molecule imaging that have been applied to the study of Ab oligomers and their mem-
brane interactions. We also summarize some of the recent insights SMM has provided into
oligomer behavior in solution, on planar lipid membranes, and on living cell membranes. A brief
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overview of the current limitations of the technique, including the lack of sensitive assays for
Ab-induced toxicity, is included in hopes of inspiring future development in this area of
research.
Keywords: Alzheimer’s disease; amyloid-beta peptide; oligomers; single-molecule microscopy; fluo-
rescence; peptide-membrane interaction
Introduction
Amyloid-b (Ab) is a peptide ranging from 39 to 43
residues in length produced by cleavage of an inte-
gral membrane protein, the amyloid precursor pro-
tein (APP).1 The Ab is present in both normal and
Alzheimer’s disease (AD) human brain tissue, albeit
at low (from picomolar to nanomolar) concentra-
tions.2,3 Ab40 is the more abundant, less amyloido-
genic form of the peptide, normally constituting
about 90% of the soluble Ab pool. The remaining
10% of the peptide is mostly Ab42, a more amyloido-
genic form with two additional hydrophobic residues
at the C-terminus. Monomeric Ab is thought to be
predominantly unstructured in solution; the middle
segment of the peptide in particular likely samples a
wide ensemble of conformations, depending on condi-
tions.4,5 At low concentrations present in vivo, the
oligomeric state of the peptide is also likely to be in
a constant state of flux, with small aggregates (from
monomers to hexamers) interconverting in a
dynamic equilibrium.6–8 Aggregation is character-
ized by an initial lag phase during which aggrega-
tion is slow but where oligomeric “seeds” form.
These then add peptide monomers in a rapid,
nucleation-dependent fibrilization to form a mixture
of fibrils and small oligomers in a stable equilib-
rium. The resulting cross-b sheet-rich fibrils repre-
sent the primary component of the plaques
originally identified by Alois Alzheimer in the brains
of patients afflicted with AD.9
The past 20 years have brought about a major
paradigm shift in the AD field. Since Alzheimer’s
initial discovery of amyloid plaques, research had
focused on Ab fibrils as a likely causative factor for
the clinical symptoms of AD, an idea referred to in
the literature as “the amyloid hypothesis.” More
recently, however, emerging evidence has prompted
a transition to an “amyloid oligomer hypothesis.”10–
12 Plaque load and insoluble Ab aggregates correlate
poorly with AD symptoms when compared with solu-
ble Ab levels and synapse loss,13–15 and oligomers
have largely been found to induce greater toxicity to
cultured cells than comparable quantities of
fibrils.16–18 These findings and others suggest that
small soluble oligomers of Ab may be the critical
neurotoxic species of the peptide.
Experimental
A number of groups have begun to utilize a unique
fluorescence microscopy-based biophysical toolset
(single-molecule microscopy, or SMM) to further
explore the structure and function of the Ab oligom-
ers. Studying these aggregates by single molecule
fluorescence techniques offers advantages over
ensemble methods because of the level of detail of
the data obtained. If behavior of a small population
in a sample is responsible for a large downstream
effect, the dominating signal from the majority can
obscure the connection.19 Populations that make
comparatively small contributions to the overall sig-
nal are ignored. With single molecule techniques,
the behavior of individual particles is monitored and
classified, greatly reducing the chances that such
important relationships in the data will be
overlooked.20
Beyond this general rationale, studying Ab oli-
gomerization and membrane binding at physiological
peptide concentrations presents a number of chal-
lenges that SMM is uniquely suited to overcome.
Soluble Ab is only found at nanomolar to picomolar
levels in the human brain.2,3 Although this can be
an obstacle for many traditional ensemble biochemi-
cal methods, such very low probe concentrations are
required to reach the low fluorophore density needed
to resolve single molecules. Efforts to pinpoint the
neurotoxic aggregates have also been complicated by
the finding that at physiological concentrations, Ab
exists as a mixture of metastable species.6–8 Single-
molecule microscopy (SMM) experiments can be con-
ducted with milliseconds-to-minutes temporal reso-
lution, offering a window into changes that occur on
this time scale. The data are snapshots of the distri-
bution of Ab species that exists at a certain moment
in time, and when aggregates exhibit structural
transitions, these changes can be visualized. Finally,
since Ab-membrane interactions are complex and
variable, binding sites may include a number of
membrane integral receptors and specific lipid moi-
eties. Binding affinity and membrane permeabiliza-
tion may be strongly affected by factors such as
membrane curvature and charge.21 The membranes
of neuronal cell somas, neurites, dendritic spines,
and postsynaptic densities are distinctive, chemi-
cally and morphologically.22–24 It follows that Ab
may have widely varying binding behavior and
membrane effects in different cellular membrane
compartments. SMM allows precise visualization of
individual oligomers and their on-cell locations.
Additionally, with the wide variety of fluorescent
probes available, SMM can easily be used to
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determine whether particular membrane molecules
may be acting as Ab binding sites.
In the past five years, SMM explorations of Ab
oligomer size, composition, and membrane interactions
have been conducted through several different
approaches, some of which are illustrated in Figure 1.
Single-molecule photobleaching, through total inter-
nal reflection fluorescence [TIRF, see Fig. 1(A)] or
confocal geometry, has been used by our group and
others to elucidate the size distribution of Ab
oligomers at physiological (picomolar–low nanomo-
lar) concentrations in solution,8,25 confirming that
very small oligomers predominate at these concen-
trations. In this approach, a single fluorophore is
covalently linked to each peptide monomer. When an
oligomer of such labeled monomers is illuminated at
the appropriate intensity, the fluorophores bleach
one at a time, creating a stepwise intensity-versus-
time trajectory in which each step corresponds to
the bleaching of a single monomer, as shown in Fig-
ure 1(C). The method is somewhat limited in that
for oligomers larger than hexamers, or so, photo-
bleaching trajectories begin to resemble an exponen-
tial decay. This tendency increases with the size of
the oligomer, so that distinguishing individual pho-
tobleaching steps (and therefore, accurately meas-
uring size) becomes difficult for very large
oligomers.
More recently, we have studied how oligomer
growth on a membrane occurs at near-physiological
concentrations for Ab40, Ab42, and mixtures of the
two by using single particle confocal-mode peak fluo-
rescence intensity and fluorescence integrated inten-
sity measurement [methods illustrated in Fig.
1(D)].26–28 In the peak fluorescence intensity
method, the peak fluorescence intensity of a detected
particle is divided by the fluorescence intensity of a
monomer to yield an estimated oligomer size.26 Simi-
larly, in the integrated intensity measurement
method, the average fluorescence intensity of a
monomer in solution is obtained by measuring the
fluorescence intensity of standards containing a
known number of fluorophores per volume unit.27
The total fluorescence intensity of a detected particle
within a volume unit is then divided by this average
monomer fluorescence intensity to obtain an
oligomer size. These two methods enabled us to mea-
sure the sizes of oligomers containing more than six
subunits. We have also combined these methods
with single molecule fluorescence resonance energy
transfer (FRET) measurements to show that Ab40
and Ab42 directly interact to form mixed
oligomers.28
The confocal two-color coincidence detection
(cTCCD) method for oligomer detection has also
proved to be a powerful technique for exploring the
oligomer–monomer equilibrium under different con-
ditions.29 In this method, illustrated in Figure 1(B),
peptide monomers are labeled with one of two differ-
ent fluorophores, with blue and red fluorescence,
respectively, and mixed before being allowed to dif-
fuse through the overlapped confocal volumes of two
separate lasers. Fluorescence emission pulses occur-
ring in only one fluorophore’s emission band are
counted as monomers, whereas simultaneous fluo-
rescence emission pulses occurring in both fluoro-
phores’ emission bands are counted as oligomers.
This preliminary “oligomer count” can then be cor-
rected to account for chance simultaneous detection
of multiple monomers labeled with different fluoro-
phores. A correction is also made in this measure-
ment for oligomers containing subunits labeled with
only one fluorophore, which are not detected by the
method.
To determine apparent oligomer size by cTCCD,
the fluorescence intensity of each detected oligomer
in the blue channel is measured, divided by the
average intensity of a monomer, and doubled. For a
large population in which the identity of the label
does not affect binding affinities, this analysis
should produce a representative size distribution. In
calculating apparent size distributions, Narayan
et al. correct for chance coincidence detection of
monomers with different labels (mentioned earlier)
as well as for estimated changes in fluorophore
emission due to intraoligomeric FRET.30 Despite
such corrections, when size distributions obtained by
cTCCD are compared with those obtained by single
molecule TIRF fluorescence intensity measurement,
the cTCCD method does result in detection of
slightly fewer dimers-to-tetramers in comparison to
the TIRF method (normalized fraction 62–63% vs.
80% with TIRF). This method of oligomer size mea-
surement may therefore be better suited for the
study of samples predominantly consisting of larger
oligomers (greater than 7–10 subunits in size). The
TIRF- or confocal-based photobleaching and confocal
integrated intensity measurement methods dis-
cussed earlier likely produce more accurate meas-
urements of the size of the smallest oligomers (up to
pentamers or hexamers).
The Dobson group and others have also begun
to explore oligomer mobility on membranes using
single-particle tracking techniques [Fig. 1(E)] in
which the two-dimensional trajectories of single par-
ticles over time are used to extract diffusion coeffi-
cients and other parameters.31,32 These can then be
used to classify the particles’ motion and make infer-
ences regarding their sizes, interactions with other
proteins, and membrane interactions.
This review will focus on the insights obtained
into Ab oligomer formation, structure, and interac-
tions with other biomolecules through recent SMM
work. We will also discuss how these results contrib-
ute to the mechanistic understanding of Ab’s mem-
brane binding behavior. Finally, the current
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Figure 1. Summary of SMM methods discussed in this review. A: In total internal reflection fluorescence (TIRF) microscopy, a
high numerical-aperture lens is used to reflect laser light off a glass slide, creating an evanescent excitation wave within the first
100–200 nm above the slide in z-direction. This technique enables selective excitation of fluorescently labeled Ab peptides
(green ellipses) adherent to the basal cell membrane or within the basal cell cytoplasm. B: In confocal two-color coincidence
detection microscopy (cTCCD), solution samples of Ab peptides are imaged in confocal mode. Each peptide is singly labeled
with one of two different fluorophores (orange and green ellipses in the image), and the sample is illuminated at each fluoro-
phore’s respective excitation wavelength simultaneously. Oligomers moving through the confocal volume are identified by coin-
cident fluorescent emission from both fluorophores. Monomers diffusing through the volume will emit only in one emission
band. C: Schematic of fluorescently labeled oligomers in the microscopy field and how the photobleaching trajectories of some
specific oligomers might appear, including background fluorescence level and noise. Counting the steps in a single oligomer
photobleaching trajectory reveals the number of fluorophores—and therefore monomeric subunits—in each oligomer. A dimer’s
trajectory has two photobleaching steps to bleach completely down to the background level, a trimer has three, a tetramer has
four, and so on. These studies can be conducted in TIRF or confocal laser scanning geometries. D: Diagram showing a region
of interest around a single oligomer (shown zoomed in at right as a smoothed three dimensional surface plot of an actual cell-
bound oligomer from Ref. 62). Confocal mode peak fluorescence intensity or integrated fluorescence intensity of the oligomer’s
intensity profile can be used to measure oligomer size. E: In the single particle tracking method, paths of particles in motion are
tracked over time. These trajectories are used to measure mean square displacement at each time point. The graph at right
illustrates how a trajectory for a particle exhibiting “directed” type motion might appear (see Ref. 31 for further details). The dif-
fusion coefficient of the particle can be obtained by calculating the slope of linear fit of the first 2–5 points on this curve.
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limitations of SMM will be covered with the goal of
outlining areas in which further innovation could
substantially advance AD research.
Amyloid-Beta Oligomer Structural Evolution
Current evidence implicates a number of different
types of oligomers in the neuronal dysfunction that
features in AD, some of which are depicted in
Figure 2. Ab dimers and trimers purified postmor-
tem from human AD brain tissue and from the
medium of cells expressing human APP have
recently been shown to induce deficits in long-term
potentiation and increases in long-term depres-
sion.33,34 The ratio of Ab40 to Ab42 in these oligom-
ers was not characterized. Another recent study
indicated that Ab40 dimers, trimers, and tetramers
exhibited nonlinear increases in cellular toxicity
with molecular weight.16
Amyloid-derived diffusible ligands, or ADDL’s,
generally prepared from synthetic Ab42, contain
oligomers from 10 kDa to 100 kDa in molecular
weight, or roughly trimers to 24-mers.35 These small
globular aggregates have been shown to bind specifi-
cally to synapses, reduce dendritic spine density,
and alter normal tau sorting and localization.36–38
Similarly sized spherical oligomers, also prepared in
vitro and containing an estimated 10–24 subunits
each, have been shown to cause immediate, cata-
strophic calcium leakage in SH-SY5Y neuroblastoma
cells.17 Of note, both preparation protocols require
exposure of the peptide to hexafluoroisopropanol, a
potentially membrane-toxic solvent, effects of which
will be discussed in more detail in the following.39
In 2006, Lesne et al. detected an Ab42 dodeca-
mer in the brains of hAPP-expressing transgenic
mice that appeared to correlate well with memory
deficits.40 Once purified and injected into the brains
of young mice, this aggregate (termed Ab*56) caused
long-term memory deficits, as measured by the Mor-
ris water maze. However, this species was not
detected in Ab purified from human AD brain.34,41
Several reports in the 1990’s indicated that
freshly solubilized Ab was capable of forming cation-
selective ion channels with stepwise conductances in
biological membranes.42,43 Pore-like protofibrillar
structures formed from Ab and other amyloid-
forming peptides were later detected by electron
microscopy and atomic force microscopy.44–46 The
imaged “annular protofibrils” were generally in the
range of 10–20 nm in diameter, with 1–2 nanometer
central pores, and appeared to contain between four
and six distinct subunits, each likely containing
multiple peptide monomers. These data were inter-
preted as evidence that Ab and other amyloid-
forming peptides may disrupt membranes in the
same fashion as bacterial pore-forming peptides.45
Most discussions of these annular structures place
their probable size between 12 and 60 monomeric
peptides.
Importantly, the vast majority of these aggre-
gates have been either purified from mammalian tis-
sue or chemically prepared in vitro at high
concentrations, providing little insight into how such
structures form and evolve at physiological concen-
trations of Ab.
SMM was first applied to this problem by Dukes
et al.25 Biotinylated FAM-labeled Ab40 was first
solubilized to 0.2–1 lM, then diluted to 30 pM and
allowed to tether to streptavidin-functionalized cov-
erslips. Imaging was performed in solution by confo-
cal scanning microscopy. Oligomer size distributions
for these samples, generated by the single-molecule
photobleaching method, consisted of mostly mono-
mers and dimers (each representing roughly 45% of
detected particles) with fewer trimers (7%) and a
smaller proportion (around 2%) of “unmeasurable”
oligomers greater than pentamers. To further test
the method, size distributions were obtained for
Figure 2. Several types of amyloid-b oligomers have been identified in the literature. These include small oligomers (dimers to
hexamers), amyloid-derived diffusible ligands (ADDL’s), the Ab dodecamer Ab*56, various ion-conducting pores and channels
identified through electrophysiology and atomic force microscopy, and annular and linear protofibrils. Estimated size ranges for
ADDL’s, pores/channels, and protofibrils to fibrils are shown in blue, yellow, and red respectively.
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samples treated with aggregation-promoting condi-
tions (aging of samples, acidic pH, 4:1 ZnCl2:Ab40
concentrations) or with aggregation inhibiting condi-
tions (in the presence of a b-sheet disrupting peptide
or the zinc chelator clioquinol). Importantly,
oligomer size distributions under these conditions
generally exhibited shifts in the expected directions,
with greater numbers of trimers to pentamers as
well as oligomers greater than pentamers being
observed under pro-aggregation conditions. The
addition of the b-sheet disrupting peptide or clioqui-
nol to Ab exposed to zinc or low pH significantly
shifted the distributions back toward monomer–
dimer predominance. As the biotinylated FAM-
labeled Ab40 was not compared with native peptide,
these results were of somewhat limited scope, but
the study thoroughly demonstrated the potential of
SMM for future study of modifiers of peptide
aggregation.
We pursued an alternate method of peptide
immobilization for SMM studies of fluorescently
labeled Ab40.8 HiLyte Fluor 488 (HL488)-labeled
Ab40 in solution at around 100 nM was further
diluted to concentrations of 0.1–1 nM, spin-coated
onto kilned coverslips, and the dry samples were
imaged by confocal scanning microscopy. In this
work and another study, we have demonstrated that
the fluorophore did not alter the ability of Ab40 to
form fibrils and permeabilize membranes relative to
unlabeled Ab40.26
Initial experiments showed that the spin-coating
SMM method could easily differentiate between a
gel-chromatography filtered sample containing pre-
dominantly monomers and dimers and an unfiltered
sample containing a wider distribution of oligomers.
Subsequently a number of methods were used to fur-
ther refine and test the accuracy of the distribu-
tions. First, as spot-detection required setting an
arbitrary detection threshold, simulated trajectories
were analyzed to determine the number of small
oligomers that were escaping detection at the uti-
lized threshold values, and a correction was applied
to the distributions to account for this. Corrected
size distributions obtained by our SMM protocol for
fluorescently labeled parvalbumin were compared to
distributions obtained by mass spectroscopy and
found to agree closely.8 Corrected SMM distributions
for HL488 Ab40 also agreed with distributions
obtained by fitting multiple Gaussians to gel filtra-
tion elution profiles for Ab40. This approach thus
provides a verified, accurate snapshot of small
oligomer size distributions at the time of spin-
coating. Baseline size distributions obtained for
Ab40 under these conditions were shifted slightly
towards dimers, trimers, and tetramers when com-
pared with the distributions observed by Dukes
et al.8,25 Given the similarities in behavior between
HL488 Ab40 and unlabeled Ab40, these results
likely do apply to endogenous peptide. Like Dukes
et al., we did observe a small population of oligomers
that were much larger than hexamers in size.8,25
Although easily detected, the sizes of these oligom-
ers cannot be accurately measured by single-
molecule photobleaching. Overall, the results of our
studies and those of Dukes et al. were quite similar,
with the samples predominantly consisting of mono-
mers (30–50% of particles), dimers (40–50% of par-
ticles), and some trimers and tetramers.8,25
A SMM approach that better estimates the pro-
portion and sizes of much larger oligomers has been
developed by the Dobson laboratory. Narayan et al.
used confocal two-color coincidence detection
(cTCCD), described in the Introduction, to character-
ize the proportion of oligomers present in samples of
HL488 Ab40 and HiLyte Fluor 647 (HL647)-labeled
Ab40 aggregated for up to 20 hours at pH 7.4, 37C,
at either 10–30 nM or 600 nM22 lM.30 Samples
were then diluted to 25–50 pM for cTCCD experi-
ments. Interestingly, in contrast to the results dis-
cussed earlier, only about 1% of the particles
detected were found to be oligomeric by cTCCD. Of
the oligomeric particles detected, Narayan et al.
found only 50% to be dimers to tetramers in size,
with the remaining oligomers being pentamers or
larger.30 Aggregation concentration (10–30 nM vs.
600 nM22 lM) did not significantly affect the
distribution.
Given the difficulties inherent in working with
Ab and the differences in methods among groups,
quantitative disparities between different laborato-
ries are almost certainly less important than quali-
tative similarities of the data across groups. Even
qualitatively, however, the results obtained by our
lab and the Lammi group differ from those of
Narayan et al.8,25,30 Oligomers detected by Ding
et al. and Dukes et al. included fairly equal mixtures
of monomers and dimers with smaller but signifi-
cant populations of trimers-tetramers, and much
smaller populations (<10% of particles) of very large
oligomers.8,25 In Narayan et al.’s study, less than 1%
of solution particles represented oligomers, and of
those oligomers, roughly 50% were greater than tet-
ramers in size.30
A number of factors may contribute to this dif-
ference. The greater numbers of dimers, trimers,
and tetramers detected by Dukes et al. and Ding
et al. may be due to “seeding” of small oligomers by
surface interactions in the previously discussed
experiments.8,25 Monomers may be more likely to
interact with monomers which are already surface-
bound, an effect which would not be observed in
cTCCD, an assay based on monitoring diffusion of
free particles through solution volumes. This is espe-
cially important to consider given that membrane
binding has frequently been shown to promote or
“seed” Ab oligomer growth. An additional rationale
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for the difference between the cTCCD method
results and the single molecule photobleaching
results is that the peptide preparation method dif-
fers vastly between the two labs. The studies by
both Ding et al. and Dukes et al. used lyophilized
peptide freshly dissolved to 0.1–1 lM in sodium
phosphate buffers at room temperature or 4C and
then diluted to picomolar or nanomolar concentra-
tions before sample preparation.8,25 Conversely, Nar-
ayan et al., before imaging used an aggregation
protocol in which samples at 10–30 nM, 600 nM, or
2 lM were heated to 37C and incubated in solution
until fibrils were detected.30 The population of
smaller oligomers (dimers to hexamers) in these
samples may be rapidly depleted by their addition to
larger oligomers or fibrils. Despite differences in
peptide treatment and results, all three studies do
provide direct visual evidence that oligomers form
and exist in a stable equilibrium at nanomolar-to-
picomolar Ab concentrations.
The utility of SMM methods for study of Ab in
solution at very low concentrations extends well
beyond the determination of which oligomers are
present in such conditions. As predicted by Dukes
et al., SMM methods have now been used to study
the effects of aggregation inhibitors on oligomers at
physiological or near-physiological concentra-
tions.25,30,47 Peptide-based inhibitors with central
sequences similar to Ab’s hydrophobic amino acids
16–21 have been shown to slow fibrillogenesis and
reduce neurotoxicity in ensemble experiments.48–51
To examine their effects on small oligomer evolution,
FAM-labeled, biotinylated Ab40 oligomer distribu-
tions were first characterized under proaggregation
conditions (pH 5.8 or 4:1 zinc:Ab ratio).47 Distribu-
tions were then measured again in the presence of
four such peptide-based inhibitors. Incubation with
10:1 inhibitor: Ab40 concentrations of any of these
four peptides significantly shifted the distributions
of small oligomers toward monomers under acidic or
zinc-rich conditions. At reduced concentrations, two
of the peptides were more effective inhibitors in
acidic conditions, whereas the remaining two were
more effective in the presence of zinc. Since pro-
posed inhibition mechanisms differ for each inhibi-
tor, these results can be used to make inferences
about the chemical nature of small oligomer forma-
tion and dissociation under each condition.
Single-molecule exploration of the effects of
chaperone protein inhibitors on Ab oligomer forma-
tion has also been conducted. The extracellular
chaperone protein clusterin was shown to greatly
inhibit oligomer formation in cTCCD experiments
performed by Narayan et al.30 Complexes containing
both clusterin labeled with AlexaFluor 647 and
HL488 Ab were detected in similar quantities to Ab
oligomers at coincident time points, indicating that
clusterin was likely directly binding to oligomers.
Furthermore, in fibril disaggregation reactions, clus-
terin was found to increase the overall final concen-
tration of oligomers and decrease the overall
monomer concentrations, in effect stabilizing the
oligomers shed by fibril dissociation. Subsequently,
similar methods were used to show that an intracel-
lular chaperone, aB-crystallin, bound to and stabi-
lized oligomers in similar fashion, though with a
shorter half-life (17 hours versus 50 hours for the
extracellular clusterin).52 These experiments were
performed at 1:1 molar chaperone: Ab monomer
ratio, which is likely equal to or less than the physi-
ological chaperone: Ab ratio. The results provide an
elegant insight into one potential mechanism by
which the body normally clears toxic Ab oligomers.
Membrane Binding Affects Oligomer Formation:
Model Membranes
The role of membrane interactions in the formation of
toxic Ab oligomers is a subject of debate. We note that
for in vitro experiments like those discussed here, tox-
icity itself is difficult to define, as the precise mecha-
nism by which Ab damages cells is as yet unknown.
Cell viability assays represent by far the most popular
method for toxicity assessment.16,18,53–55 However,
this method has the disadvantage of being the last
possible indication of the peptide’s toxic effects. Elec-
trophysiological methods for assessing neuronal dys-
function and membrane conductivity are also
commonly utilized to detect more subtle, earlier detri-
mental effects of Ab exposure. Observed electrophysi-
ological signs of Ab-induced toxicity have included
decreased firing frequency on multielectrode arrays,
decreased long-term potentiation, and simply ion leak-
age across membranes.26,34,56–58 Increased intracellu-
lar calcium concentration and abnormal synaptic
spine density and morphology have also gained accep-
tance as signs of Ab-induced toxicity.17,27,37,59,60
Therefore, for the purposes of the current discussion,
Ab-induced toxicity refers to results obtained by any
of these methods of assessing cellular death or
dysfunction.
A number of groups have found that Ab preag-
gregated at high concentrations induces greater tox-
icity than monomeric or fibrillar Ab, implying that
oligomers formed at high concentration in solution
(without contact with biological membranes) are
capable of interacting with cell membrane moi-
eties.17,53 Although Ab may be present locally at lM
concentrations, the global presence of only nanomo-
lar concentrations provokes the question of whether
oligomers formed at very high concentrations are
physiologically relevant. Additionally, these reports
to some degree contradict older evidence that treat-
ment of biological membranes with unaggregated Ab
leads to formation of cation-selective, stepwise con-
ductance changes.42,43 The recent usage of
membrane-damaging solvents in Ab peptide
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preparation has further complicated these questions.
Demuro et al. in 2005 reported that oligomers pre-
pared in vitro produced immediate, catastrophic cal-
cium leakage in SH-SY5Y cells.17 The peptide used
in these experiments, however, had been treated
with hexafluoroisopropanol (HFIP) before the oligo-
merization protocol.17 A later study showed that
traces of the HFIP may have remained in the oligo-
merized samples following evaporation, destabilizing
membranes, and effectively inducing calcium
leakage.39
Understanding the relative importance of spe-
cific Ab oligomers in the mechanism of toxicity
requires a better knowledge of which oligomer types
form and interact with membranes at low concentra-
tions (in the absence of membrane-disrupting sol-
vents). We must also improve our understanding of
how oligomers formed in solution are related to
those formed in contact with membranes under dif-
ferent conditions. The use of single molecule fluores-
cence imaging enables direct visualization of
membrane-bound monomers and oligomers in multi-
ple environments and has already helped shed light
on these questions.
In our studies of monomeric Ab40’s interactions
with anionic lipid bilayers, we showed that binding
and oligomerization occur in two separate phases.61
Briefly, planar membranes composed of a 1:1 ratio
of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) to 1-palmitoyl-2-oleoyl-sn-glycero-3-[phos-
pho-rac-(1-glycerol)] (POPG) were incubated with
concentrations of 2–100 nM HL488 Ab40 for up to 6
days.61 The use of anionic membranes was moti-
vated by results of ensemble experiments performed
in our laboratory and by others indicating that nega-
tively charged membranes bind Ab more tightly and
become especially susceptible to permeabilization by
the peptide.21 Across this concentration range, initial
monomer binding occurred uniformly at an estimated
density of 9 3 108 monomers per cm2. Binding
exhibited first-order kinetics and was essentially
irreversible, with a koff rate less than 2 3 10
26 s21.
The dissociation constant for this concentration
regime was calculated to be <470 pm. The bound
monomers were highly mobile, with fluorescence
recovery after photobleaching (FRAP) experiments
revealing that both the lipid molecules and the uni-
formly bound, diffusing monomeric Ab40 had diffu-
sion coefficients around 2 lm2/s. The appearance of
immobilized oligomers occurred within as little as 2.5
hours on membranes exposed to 100 nM solution of
Ab40. However, immobilized oligomers were not
observed for several days on membranes exposed to
2 nM peptide or preincubated for 1 day with 2 nM
peptide and then maintained in solution without Ab.
A much greater population of very large oligomers
(estimated size 30–160 monomeric subunits) was
observed in the 100 nM population, with the 2 nM
population containing primarily dimers to dodeca-
mers. Membranes pretreated with 2 nM peptide and
then imaged after an additional 4.5 days’ incubation
at 0 nM or 2 nM peptide had nearly equivalent
immobile oligomer densities. However, immobile
oligomer density was roughly three times higher at
the 100 nM concentration. We concluded that at very
low solution peptide concentrations, membrane-
bound oligomers formed primarily by association of
the diffusing membrane-bound monomer population
rather than by direct insertion from solution.61 At
higher concentrations, however, a large portion of
the membrane-bound oligomers had to form either
by direct insertion of preformed oligomers from solu-
tion or by rapid replenishment of the membrane-
bound monomers used in oligomer formation by solu-
tion monomers.
Combining SMM with other electrophysiological
or optical techniques allows one to correlate the
presence of specific bound oligomers with ion move-
ment across membranes. Our group performed such
studies using “black lipid” membranes (prepared
from a 7:3 ratio of diphytanoylphosphatidylcholine
to diphytanoylphosphatidylserine) incubated with 10
nM to several hundred nanomolar solutions of
HL488 Ab40.26 Similar initial binding of a uniform,
diffusing monomer population was observed, with
binding density estimated at 5 3 108 monomers per
cm2. This population was not found to induce ion
conductance in the membrane. In fact, conductivity
was only observed when immobile oligomers of size
greater than pentamers to octamers were present,
and it was found to increase in the presence of
larger oligomers. The intermediate-sized oligomers
were found to be stable, remaining immobile for sev-
eral hours in the black lipid membrane. At very
high (>200 nM) peptide concentrations, a third type
of membrane-bound peptide aggregates was
observed. These aggregates were much larger than
the optical diffraction limit, changed significantly in
size and structure over the course of several hours,
and massively disrupted the membranes. Thioflavin
T binding experiments performed using unlabeled
peptide under conditions consistent with formation
of both intermediate-sized oligomers and the much
larger aggregates indicated that both classes of pep-
tide aggregates possess significant b-sheet
structure.26
Insight from model membrane experiments thus
indicates that at very low concentrations (on the
order of 1 nM), Ab oligomer formation occurs pri-
marily by association of membrane-bound, rapidly
diffusing monomers.61 However, at higher concentra-
tions, direct insertion of solution-formed oligomers
may occur. Intermediate sized-oligomers appear to
be generally immobile within planar model mem-
branes, possibly due to full insertion through the
bilayers and interactions with the underlying slides.
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Furthermore, oligomers containing more than five to
six monomeric subunits may be capable of allowing
ion conductance across membranes, and these
intermediate-to-larger sized oligomers have some b-
sheet structure.26
Binding and Oligomer Formation: Live Cell
Membranes
Characterizing Ab’s interactions with model mem-
branes has yielded significant quantitative data on
peptide binding and oligomer formation over hours-
to-days. However, model membranes are signifi-
cantly less complex in composition and dynamics
than live cell membranes. To gain insight into how
these factors affect Ab-membrane binding and
oligomer formation, we applied 50 nM HL647 Ab40
peptide to SH-SY5Y neuroblastoma cells and imaged
the cells after a 10-minute incubation.27 Immobile
oligomer size was determined by integrated fluores-
cence intensity measurement. Interestingly, under
these conditions, we did not find evidence of a uni-
formly bound, diffusing population of monomers.
However, immobile, cell surface-localized oligomers
ranging in size from dimers to hexamers and larger
were detected. These results led us to conclude that
properties of the cell membrane must facilitate rapid
in-membrane oligomer growth or preferential bind-
ing of oligomers over monomers.
Consistent with this hypothesis, the observed
structures were found to be slightly larger in size
than the oligomers nonspecifically bound to glass
slides under the same conditions.27 Although brief
incubation in cell growth medium on glass slides did
appear to induce increased Ab40 oligomerization
when compared with Ab40 spin-coated from buffer,
cell-bound oligomers were even greater in size. The
majority of cell-bound oligomers colocalized with a
membrane-specific dye. About 10% of cells loaded
with a fluorescent calcium indicator did exhibit
minor fluorescence increases within the first 10
minutes of exposure to 50 nM labeled or unlabeled
Ab40. We concluded that on cells, as on black lipid
membranes, the observed small oligomers may
induce very low-level calcium conductivity. Occasion-
ally, very high intensity fluorescent structures, com-
posing less than 10% of the total fluorescent
particles, were also observed on cells in these experi-
ments and likely represented aggregates containing
greater than 20 peptide monomers.27
Further experiments using neurites of primary
rat hippocampal cells gave initially similar results
at even lower Ab concentrations.62 Plated cells were
incubated with 1 nM HL647 Ab40 or Ab42 for 10
minutes, gently washed three times so as to pre-
serve the cells’ adherence to the slides, and imaged
in confocal mode. Generally immobile small oligom-
ers of HL647 Ab40 were detected on cell neurites
within 10 minutes incubation at 1 nM, as depicted
in Figure 3. The size distribution for HL647 Ab42
oligomers was similar. Interestingly, further incuba-
tion of the cells without solution peptide for up to 48
hours resulted in a small but significant decrease in
on-membrane oligomer size and a decrease in the
total amount of peptide bound. Prolonged incubation
of the cells with peptide in solution resulted in no
significant change to the size distribution for Ab40,
but a significant (if small) shift toward larger
oligomers for Ab42. In addition, we recently
obtained very similar results using 2 nM HL555
Ab40 and 2 nM HL647 Ab42, the only difference
being a slight trend toward larger oligomers in the 2
nM Ab42 samples (likely a result of the doubled
incubation concentration).28 No toxicity was
observed by assessment of calcium transient fre-
quency, fluorescent calcium indicator activation, or
spine density at 1 nM peptide exposure over these
time scales.
An alternate approach to the study of Ab inter-
actions with live cell membranes has been taken by
Narayan et al. using dual-excitation TIRF micros-
copy.31 Similarly to cTCCD, in this method, samples
of a 1:1 mixture of HL488 and HL647-labeled Ab
were coexcited with two lasers. Whereas in the
cTCCD method, diffusion of both fluorophores at the
same time through a confocal volume is counted as
an oligomer, in this study, detection of both fluoro-
phores at the same location in the TIRF x-y plane is
counted as an oligomer. For the TIRF experiments,
1:1 mixtures of HL488 and HL647-labeled Ab40 or
Ab42 were incubated at low micromolar
Figure 3. Neurites of primary rat hippocampal cells treated
for 10 minutes with 1 nM HL647 Ab40 (top row) show puncta
of high fluorescence intensity corresponding to labeled
monomers and oligomers. Cells treated with unlabeled Ab40
(bottom row) were used as controls. Scale bars, 5 lm.
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concentrations to promote in-solution formation of
oligomers. This preaggregated peptide was applied
to suspended mouse hippocampal cells at 500 nM.
Following a 15-minute exposure, the cells were
washed, centrifuged, resuspended, and allowed to
reattach to polyethylene glycol-coated slides for 10
minutes. The proportion of cell-bound particles
counted as oligomers was between 40 and 70% for
Ab42 and 10 and 40% for Ab40. These were signifi-
cantly higher proportions than for peptide in solu-
tion. Additionally, when oligomer sizes were
estimated, the cell-bound oligomers for both peptides
were found to be larger than oligomers in growth
medium. For both peptides, 40% of the cell-bound
oligomers were greater than five subunits in size.
This represents a significant increase over the
roughly 10% of peptide-bound particles we observed
in this size range; the disparity is most likely due to
the preaggregation of the peptide and the signifi-
cantly higher peptide concentrations (500-fold)
employed in these experiments.27,31,62 Differences in
binding affinity between small and large oligomers
may also contribute, as the multiple washings
described earlier might detach smaller oligomers. It
is also possible (if somewhat unlikely) that resus-
pending the cells after Ab exposure and allowing
them to reattach selects for a subpopulation of cells
that has larger Ab aggregates bound. Additionally,
the size distributions of oligomers may be affected
by the part of the cell being imaged—our study
focused on the neurites, whereas Narayan et al.
examined cell soma.31,62 Differences in membrane
curvature and charge between these structures
could significantly affect peptide binding and
oligomerization.
Despite these differences, a key point is that
both studies detected significantly larger oligomers
on the membrane than in solution. As Narayan
et al. suggest, this result may be due to preferential
binding of oligomers in comparison to monomers.31
Another explanation suggested by multiple previous
studies is that membrane binding catalyzes oligomer
formation from bound, diffusing monomers and very
small oligomers. Interestingly, Narayan et al. do
detect a small population of fast-diffusing, most
likely monomeric species using single particle track-
ing methods.31 We note that sparsely bound, rapidly
diffusing monomer would not necessarily be detected
above background in our confocal method, given the
difficulty of detecting this lower signal in the context
of cellular autofluorescence.27
As discussed earlier in the summary of the
model membrane work, both mechanisms could cer-
tainly be at play, with direct binding from solution
generally predominating at higher concentrations
and in-membrane oligomer formation dominating at
lower ones. As recently hypothesized by Zhang
et al., Ab oligomers formed from monomer within
the membrane and those formed in solution (before
membrane-binding) may even induce toxicity by two
entirely separate mechanisms.63
Synergy of AB40 and AB42
A number of recent studies have raised interest in
the role of Ab42:Ab40 ratio in peptide aggregation
and interaction with cells.55,56 We explored this
issue by comparing on-membrane oligomer growth
of a 1:1 mixture of the two peptides to that
observed for each peptide alone.62 Relative to homo-
geneous Ab40 or Ab42, the size distribution for
cell-bound mixed 1 nM peptide after 10 minutes
was significantly shifted toward monomers and
dimers. Perhaps more intriguingly, a very signifi-
cant oligomer size increase was observed for the
mixed peptide after 24–48 hours at 1 nM. This
increase was much larger than that observed for
either peptide alone, with over 70% of the total pep-
tide residing in oligomers greater than trimers
after 1–2 days. Additionally, the total amount of
peptide bound doubled for the mixed peptide over
this time, indicating that much of this growth was
due to new binding of peptide from solution. These
results indicate that cells either (A) have a higher
binding capacity for oligomers of the mixed peptide
or (B) have a reduced ability to clear oligomers of
the mixed peptide when compared with either Ab40
or Ab42 alone.
FRET experiments with HL555 Ab40 and
HL647 Ab42 confirmed that mixed oligomers do in
fact form.28,62 Following this observation, we contin-
ued to utilize these two peptides to further examine
the mechanism of oligomer growth on neurites
exposed to mixed Ab40 and Ab42. We found that
when cells were incubated with mixed peptide for a
full 48 hours, the additional oligomer growth beyond
that observed at 10 minutes could be accounted for
primarily by increases in Ab42 fluorescence. This
suggests a mechanism by which mixed Ab42:Ab40
oligomers act as “seeds” for binding of additional
Ab42 subunits. Alternately, cells may have a
reduced ability to clear mixed oligomers when com-
pared with pure Ab42 or Ab40, allowing mixed
aggregates to dwell at the membrane longer and in
turn maximizing their ability to allow Ab42 to bind.
In either case, this is an intriguing result, as high
Ab42:Ab40 ratio appears to result in earlier age of
Alzheimer’s disease onset in human brain,64,65 and
mutations in presenilins 1 and 2 that cause familial
AD increase this ratio in transfected cells and trans-
genic mice.66–68 It is difficult to draw conclusions at
this point as to the structural explanation for this
phenomenon. However, the observation does make
clear that the presence of Ab40 is necessary for the
increased binding of Ab42 over time. Further studies
will be necessary to understand the molecular inter-
actions involved.
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Mobility on membranes
Surface mobility of membrane-bound oligomers is a
question of significant interest. In our studies of
neurite-bound Ab40 and Ab42, a large number
(roughly 70%) of small oligomers were found to be
immobile enough for fluorescence intensity measure-
ment, which likely reflects a “confined” type of
motion on the membrane. Several groups have
looked into this question in more detail using single-
particle tracking methods that allow diffusion coeffi-
cients to be extracted by fitting the initial 2–5 points
of a mean square displacement (MSD) versus time
plot.31,32,69,70
In one set of single-particle tracking experi-
ments, Calamai et al. applied preaggregated Ab42 to
SH-SY5Y cells at 10 lM. They then incubated the
cells with antibodies specific for prefibrillar confor-
mation (I11) and fibrillar conformation (OC) to label
the bound oligomers with quantum dots for particle
tracking.32 While no measurement of oligomer size
was obtained, I11 antibodies reportedly bind to
oligomers from 8 kDa (dimers) to 100 kDa (25-mers),
and OC antibodies bind to oligomers from 8 kDa
(dimers) to 250 kDa (75-mers) in size. Fibrillar con-
formation (OC-labeled) oligomers tended to exhibit
the least motion, with 75% of particles exhibiting a
“confined” type motion as categorized by the curva-
ture of their MSD versus time plot. Among the prefi-
brillar (I11-labeled) aggregates, 50% of particles had
plots typical of “confined” motion, over 25% had
plots typical of Brownian motion, and roughly 10%
had plots typical of more rapid “directed”-type
motion. Thus, the majority of oligomers overall
exhibited highly restricted motion; median diffusion
coefficients for prefibrillar (I11) and fibrillar (OC)
aggregates, respectively, were 4 3 1023 lm2/s and
9 3 1024 lm2/s. Of note, diffusion coefficients
obtained with TAMRA-labeled Ab42 did not differ
significantly from those obtained with quantum dot-
labeled Ab42, implying that the mobility is not
affected by the size of the label. Calamai et al. sug-
gest that the oligomers exhibiting “directed” motion
may be contained in intracellular vesicles, a likely
possibility given recent reports that extracellular Ab
can be taken up by cells.18,71
The limited mobility of the majority of the
oligomers is more difficult to rationalize. In further
experiments, Calamai et al. found that quantum-dot
labeled Ab42 oligomers bound to synthetic giant uni-
lamellar vesicles (GUV’s) were much more highly
mobile, with a median diffusion coefficient of 1.1 3
1021 lm2/s.32 This value is only one order of magni-
tude lower than the 2 lm2/s value we obtained in
FRAP experiments with diffusing monomers on pla-
nar lipid bilayers. In more recent single particle
tracking experiments, we have obtained similar val-
ues for the diffusion coefficients of mobile monomers
and dimers on planar lipid membranes (Chang, C. C.,
unpublished data). These results suggest, as the
authors note, that interaction with moieties present
only in cells may be responsible for the “confined”
type motion of most oligomers.32
Cell-bound oligomer motion was also assessed
by single particle tracking in one of the studies by
Narayan et al.31 For these experiments, an incuba-
tion concentration of 1 lM Ab42 or 2 lM Ab40 was
employed on mouse hippocampal neurons. As previ-
ously discussed, Narayan et al. did detect a highly
mobile population of likely monomers on the mem-
brane in Ab40-treated samples (estimated diffusion
coefficient around 1021 lm2/s).31 When only Ab42
species undergoing FRET (presumed oligomers)
were analyzed, 20% of particles had diffusion coeffi-
cients (D) clustered around 5 3 1024 lm2/s, 35%
had D around 3 3 1023 lm2/s, and 45% had D
around 4 3 1022 lm2/s. For Ab40 species under-
going FRET, 42% of particles had D around 4.5 3
1023 lm2/s, and 58% had D around 5 3 1022 lm2/s.
Overall, diffusion coefficients tended to decrease
with oligomer size, indicating that larger oligomers
diffused less rapidly. Roughly half of the observed
species, overall, had diffusion coefficients more typ-
ical of “confined” motion or very slow diffusion.
Again, the authors suggest that interaction with a
cytoskeletal component or other semi-immobile
membrane component may be responsible for this
observation.31
If Ab on cell membranes is interacting with
specific proteins or other molecules within the
membrane, what are the other members of these
Ab-containing complexes? Abundant ensemble data
has provided evidence for so-called Ab receptors
and has been discussed elsewhere.70,72–74 However,
some insight has also been gained from further sin-
gle particle tracking experiments. Briefly, one
group found that exposure of rat hippocampal neu-
rons to pre-formed Ab42 oligomers reduced mobility
of synaptic and extrasynaptic mGluR5 receptors,
and moreover, Ab oligomers and mGluR5 receptors
appeared to codiffuse or associate.70 Recent explora-
tions by Calamai et al. into amyloid oligomer effects
on GM1 gangliosides using single particle tracking
showed that the pancreatic amyloid-forming pep-
tide amylin aggregates significantly slowed GM1
diffusion, but Ab42 did not.69 These studies illus-
trate the potential of the single particle tracking
technique for further localizing Ab binding on the
cell. Our preliminary studies on fixed cells revealed
no colocalization of single Ab oligomers with pre-
synaptic or postsynaptic markers, but a slight pref-
erence for association with dendrites over axons
was observed.62 As imaging and labeling techniques
continue to improve, single particle tracking meth-
ods will likely provide much more insight into the
mechanism behind oligomers’ limited motion on the
membrane.
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Current Limitations
The discussion above demonstrates that single mole-
cule techniques have contributed significant new
knowledge of Ab oligomers and their membrane
interactions. However, we note that these techniques,
like all research methods, do have their limits. Par-
ticularly in neuronal primary cells, autofluorescence
can present significant challenges to the detection of
single fluorophores on the cell surface. This obstacle
can generally be overcome by focusing on regions of
the cell with low autofluorescence (for example, neu-
rites), using techniques that illuminate only thin sec-
tions of the cell (confocal or TIRF geometries), and
working with long-wavelength fluorophores when
possible (e.g., HiLyte Fluor 647). A more unexpected
roadblock has been the lack of observable Ab-
induced toxicity at the physiological concentrations
and brief time scales often required for these techni-
ques. Of the studies reviewed here, none have
reported correlation between specific oligomeric spe-
cies and cellular toxicity. This may simply be a result
of the previously discussed insensitivity of current
methods of assessing toxicity. Alternately, SMM
experiments have hitherto utilized mainly synthetic
Ab, and it is possible that endogenous Ab has chemi-
cal or structural characteristics or undergoes modifi-
cations which render it significantly more toxic than
synthetically prepared peptide. Purifying and label-
ing endogenous Ab would likely alter these traits.
Using fluorescently labeled antibodies or other exter-
nal labeling agents on endogenous Ab is a promising
technique. However, no antibodies to specific stoichi-
ometric species exist to our knowledge. In addition to
these concerns, the protocols required for observable
binding can be harsh and may in some cases require
long out-of-incubator time periods, making cell via-
bility and membrane integrity a concern even in
control-treated cells.31
Certain potential pitfalls are inherent to the use
of fluorescently labeled peptides as well. Fluorescent
tags could in theory significantly alter the behavior
of the Ab peptide. Data to date suggests that
N-terminal tags do not introduce any changes detect-
able by traditional methods of monitoring aggrega-
tion or membrane permeabilization,8,26 but it is
essential to remain mindful of the possibility that
labels at other locations or with charges or sizes of
unusual magnitude may strongly affect oligomeriza-
tion and fibril formation. Additionally, for any meth-
ods which utilize fluorescence intensity to measure
oligomer size, it is important to compare lifetimes of
aggregates of various sizes to determine whether the
fluorescence is reduced by quenching, particularly
for large peptide assemblies.26–28 When used in solu-
tion, the cTCCD method requires corrections for the
slower diffusion of larger particles, as large aggre-
gates will appear brighter than they should because
of increased time spent in the confocal volume.29
Conclusions and Future Directions
Despite the limitations of the technique, single mole-
cule microscopy experiments have provided signifi-
cant insight into Ab’s behavior in solution at
physiological concentrations, its direct interactions
with model lipid bilayers and living cell membranes,
and some of the conditions that may affect its aggre-
gation in a physiological setting.
SMM measurements confirm that at picomolar to
low nanomolar concentrations in solution, monomers
and very small oligomers dominate the peptide’s size
distribution. Membrane interactions of the peptides
appear to be highly sensitive to solution peptide con-
centration and membrane composition and geometry.
At low solution concentrations (on the order of 1–2
nanomolar), monomers bind to membranes homogene-
ously and diffuse rapidly. Slow formation of oligomers
from association of rapidly diffusing monomers
appears to be the dominant oligomer growth mecha-
nism under these conditions, with the processes of
binding and oligomerization being very distinct. At
higher concentrations (>100 nanomolar) and on the
more complex membranes of living cells, distinguish-
ing the two processes becomes more difficult. Direct
insertion of solution-formed oligomers may play an
increased role, but formation of oligomers from
membrane-bound diffusing monomers is also likely to
occur more rapidly. In either case, membrane exposure
definitely either (A) catalyzes formation of larger
oligomers than are present in solution or (B) promotes
rapid binding of the largest oligomers from solution
once they form, creating an imbalance between the in-
solution and on-membrane oligomer size distributions.
From the SMM data, it is unclear whether these
larger membrane-bound oligomers can effectively
disrupt normal cellular processes. Species greater
than hexamers induce conductivity of model mem-
branes, and neuroblastoma cells do exhibit some
low-level, sporadic calcium leakage under conditions
in which these oligomers are observed.26,27 However,
the leakage is of much lower magnitude than that
observed by previous groups at higher Ab concentra-
tion and using peptide treated with the membrane-
toxic solvent hexafluoroisopropanol (HFIP).17 In pre-
liminary experiments with rat hippocampal neurons,
no peptide-induced changes were observed in cal-
cium transient frequency, spine density, or intracel-
lular calcium concentrations. It may be that
previous metabolic insults or aging-related inflam-
matory changes are necessary for neurons to become
susceptible to oligomer-mediated toxicity at the pep-
tide concentrations used for SMM experiments.
Single particle tracking experiments by multiple
groups have documented that 50–70% of live cell
membrane bound oligomers are relatively immobile
or “confined” in their diffusion.31,32,62 We have
postulated that the immobility of oligomers bound to
model membranes is likely due to full insertion
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through the lipid bilayers and binding to the under-
lying glass surfaces.61 Similar mechanisms may be
at work on cells, with fully membrane-integral Ab
oligomers gaining the ability to interact with cytos-
keletal elements underlying the membrane. How-
ever, there is also potential for surface-bound
oligomers to be interacting with any number of
membrane-integral protein or lipid-protein com-
plexes. Further experiments will be required to
determine which process, if either, is responsible for
the peptide’s relative immobility. Regardless of the
mechanism, an important point is that the same
interactions that restrict these oligomers’ mobility
may stabilize them conformationally. This phenom-
enon could lengthen “open” times if oligomer aggre-
gates are behaving like ion-conductive pores or
channels. It could also stabilize the exposure of
aggregation-promoting portions of the oligomers to
solution Ab, increasing membrane-bound oligomers’
abilities to act as seeds for further oligomer growth.
We note that similar proportions of the oligomers
appear to be immobile at the very low exposure con-
centrations used in our experiments and at the
much higher Ab concentrations used by Narayan
et al. and Calamai and Pavone.31,32,62 The mecha-
nism underlying oligomer immobility does not
appear to be affected by solution peptide concentra-
tion, indicating that “immobile” binding sites become
occupied at very low solution peptide concentrations.
SMM experiments have similarly begun to pro-
vide very significant insight into the effects of
changes in the solution and membrane milieu on oli-
gomerization. Previously identified peptide-like aggre-
gation promoters and inhibitors have chemical effects
on very small, physiological-concentration oligomers,
which are largely similar to their effects on aggre-
gates of much greater size at higher concentrations.47
The chaperones clusterin and ab-crystallin are capa-
ble of stabilizing these oligomers and slightly larger
ones.30,52 These experiments illustrate the power of
SMM methods for comparing the effectiveness of dif-
ferent aggregation modifiers on peptide in solution,
before any interactions with membranes. Single-
molecule FRET studies have conclusively demon-
strated that formation of heterogeneous, mixed Ab40,
and Ab42 oligomers does occur, and these mixed
oligomers can act as seeds for downstream binding of
more Ab42, potentiating greater oligomer growth
than occuring with either peptide alone.28 This study
illustrates the potential of the method for further
exploration into Ab’s interactions with other peptides
and membrane components.
The future of single molecule methods in the
study of Ab holds significant promise. With the
strong grounding we have discussed here, further
development of these techniques could proceed in a
number of directions. Our ability to detect
membrane-bound Ab currently supersedes our abil-
ity to detect oligomer-induced toxicity. More sensi-
tive methods of detecting Ab-induced changes to
normal physiology need to be developed, so that sin-
gle membrane-bound oligomers can be correlated
with specific localized toxic effects. One group has
already utilized an optical patch-clamping method to
identify Ab-induced sites of calcium leakage on frog
oocytes.60 This method could be combined with
single-molecule imaging of the cellbound Ab aggre-
gates to assess the size of specific oligomers inducing
leakage. SMM could also be combined with single-
channel patch clamping for similar purposes, or
with fluorescence-based assessment of dendritic
spine structure over time. The Ab40/Ab42 relation-
ship should be further explored, and other possible
protein or lipid “seeds” or binding partners for Ab
should be studied at physiological concentrations
using SMM. Finally, the reasons for oligomers’ appa-
rent immobility on membranes should be further
explored, as the responsible interactions may be
directly or indirectly related to the oligomers’ toxic-
ity. Many avenues are open for further study, and
single-molecule fluorescence techniques represent a
powerful tool for ongoing research into the
molecular-level role of Ab in the development of Alz-
heimer’s disease.
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